Last quarter performance
Latest 13F value ($M):
13F allocation to recent biotech IPOs:
% change from previous 13F value:
Net gain / (loss) in recent biotech IPO investments, today vs. last 13F 1:
Net gain / (loss) in recent biotech IPO investments, most recent 13F vs. previous 13F:
1 Assumes no change in shares owned from last 13F to today
Last quarter activity
Net buys / (sells) in recent biotech IPO investments, most recent 13F vs. previous 13F:
Number of new recent biotech IPO positions established:
Number of recent biotech IPO positions closed:
Number of recent biotech IPO positions increased:
Number of recent biotech IPO positions decreased:
(based on 13F for quarter ending 09/30/2022)
| Company name | Ticker | Latest market cap | Current value 1 | Value at 09/30/2022 | Unrealized gain / loss since last 13F date | Unrealized gain / loss during last 13F period | % of 13F AUM | Shares bought in last quarter (% change in position) | Dollar value of shares bought in last quarter 2 | Shares sold in last quarter (% change in position) | Dollar value of shares sold in last quarter 2 |
|---|
1 assumes no change in share count since latest 13F
2 based on VWAP during quarter position was established
| Company name | Ticker | IPO date | IPO amount | IPO post-money | Latest market cap | Est. amount invested in IPO * | Amount invested pre-IPO | Percent of company purchased in IPO | Stage at IPO |
|---|
* based on 13F filed for same quarter as IPO. 13F shares may not reflect shares purchased in IPOs
Shares held at end of quarter; red cells indicate shares sold in quarter; green cells indicate shares purchased